Additional screening for DCM includes monitoring for elevations in either a marker of cardiac stretch, blood levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), or a marker of cardiomyocyte damage, cardiac-specific troponin I (8–10). The gene discussed is NPPB; the disease is familial dilated cardiomyopathy.